Nurix Therapeutics is trading 4.1% up at $23.07 in after-hours trading following its October 12, 2026, third-quarter results and corporate update. - Revenue was $673.1 million, largely from Roche collaboration licensing revenue; cash and marketable securities were $1.1 billion. - Nurix announced the first patient dosed in Phase 3 DAYBreak CLL-306; reports said shares initially rose nearly 8% before falling, citing increased operating expenses—a move that differs from the provided after-hours quote used here.